Welcome to our dedicated page for Adm Tronics news (Ticker: ADMT), a resource for investors and traders seeking the latest updates and insights on Adm Tronics stock.
ADM Tronics Unlimited, Inc. (ADMT) delivers innovative electronic device solutions through integrated design, engineering, and FDA-registered manufacturing services. This news hub provides investors and industry professionals with essential updates on the company’s medical technology developments, regulatory milestones, and strategic initiatives.
Access real-time updates on ADMT’s proprietary medical devices including therapeutic technologies, contract manufacturing partnerships, and R&D advancements. Our curated news collection features earnings reports, product launch announcements, and compliance updates – all critical for understanding this full-service medical device developer’s market position.
Key coverage areas include innovations in non-invasive therapeutic systems, FDA-compliant manufacturing updates, and strategic collaborations within the healthcare technology sector. Bookmark this page for streamlined tracking of ADMT’s progress in merging engineering excellence with medical innovation.
ADM Tronics (OTCQB:ADMT) reported financial results for Q2 FY2025. Revenues increased 12% to $1,697,881 for the six months ended September 30, 2024, compared to $1,516,821 in the same period last year. The company posted income from operations of $118,423 versus a loss of $365,446 in the prior year period. For Q2, revenues grew 11% to $840,036, though operating loss was $45,858 compared to a $228,105 loss last year. The improvement was driven by increased revenues in engineering and chemical segments. The company continues R&D on its proprietary non-invasive musculoskeletal pain therapy device, planning an FDA 510(k) submission.
ADM Tronics Unlimited, Inc. (OTCQB:ADMT) reports positive financial results for the first quarter of Fiscal Year 2025 ended June 30, 2024. Key highlights include:
- Revenue increased by 12% to $857,845 compared to $762,689 in the same period last year
- Net profit of $272,168, a significant improvement from a net loss of $132,261 in the previous year
- Profit from operations of $164,281, compared to a loss of $137,796 in the same quarter last year
- Gross profit increased to $520,903 from $325,142
ADMT completed R&D for its Vet-Sonotron® device and is advancing the human medical version. The company plans to pursue FDA 510(k) submission for the human Sonotron®, targeting non-drug pain treatment.
ADM Tronics Unlimited, Inc. (OTCQB:ADMT) reported results for fiscal year ended March 31, 2024. Key highlights:
- Revenues decreased 19% to $2,965,406
- Gross profit fell to $1,116,422 (38% margin) from $1,657,902 (45% margin)
- Net loss widened to $877,222 from $96,322
- R&D expenses increased to $576,903 from $541,184
- Focused on finalizing Vet-Sonotron® technology for veterinary market
- Developing medical version of Sonotron® for human use
- Reduced engineering services revenues due to prioritizing proprietary product development
- Recorded reserve for past due accounts receivables
- Faced challenges from inflation and supply chain issues
FAQ
What is the current stock price of Adm Tronics (ADMT)?
What is the market cap of Adm Tronics (ADMT)?
